Orgenesis

Leading the revolution in regenerative cellular therapy

Manufacturing: MaSTherCell

Orgenesis is a premier service provider in the regenerative medicine industry. Orgenesis provides contract development and manufacturing (CDMO) services for many of the world’s leading pharmaceutical and biotech companies, as well as research institutions and hospitals involved in cutting edge cell therapy.

Learn about our Manufacturing

Advanced Cell Therapies

Transdifferentiation Platform
Lead Indication: Insulin Dependent Diabetes

Through our subsidiary Orgenesis Ltd., Orgenesis has developed a unique, proprietary technology platform that transforms the patient’s own liver cell into a fully functional and physiologically glucose-responsive insulin-producing cell, designed to provide long-term insulin independence. 

Explore our Technology

Manufacturing with MaSTherCell

MaSTherCell is a leading contract development and manufacturing (CDMO), with rapidly growing global operations servicing many of the world's leading healthcare companies and organizations through a scalable, highly-efficient, commercial manufacturing platform that reduces costs and time-to-market for advanced cell therapies.

MaSTherCell provides its customers: (i) process and assay development and optimization services; and (ii) the highest quality accredited contract manufacturing services (iii) Logistic services for collection of starting material (biopsies and so on) and supply of released product.

View Our Manufacturing

Dedicated to Curing Insulin Dependent Diabetes

Orgenesis, Ltd. is working on developing a practical cure for insulin dependent diabetes using Autologous Insulin Producing ("AIP") cells and the technology of "cellular transdifferentiation" to transform an autologous adult liver cell into a fully functional and physiologically glucose-responsive insulin-producing cell.

The platform technology seeks to provide diabetes patients with long-term insulin independence, which would transform the lives of these patients suffering from this debilitating disease.

What We're up to

Latest Events

Oct 18, 2017 • 9:30am PST

BIO Investor Forum

View all Events

Investor Relations

View Investor Relations

Orgenesis Inc.

OTCQB: ORGSD Symbol
Price
Change
Market Cap
Volume
Day Range
52 WK Range